Reverse-path forwarding

Zip Annual User Conference to Feature Speakers from Discover Financial, Figma, Kearney, Northwestern Mutual, OpenAI, Snowflake, Two Sigma, UC Irvine Health and WestCap

Retrieved on: 
Friday, October 6, 2023
Professional Services, Payments, Technology, Finance, Software, Fintech, Nicollet Mall, Senior, UC, Airbnb, Humble Bundle, Risk, University of California, Irvine, Heart, OpenAI, CPO, Reverse-path forwarding, Growth, SVP, Procurement, CFO, Two Sigma, Sigma, Discover Financial, One Sansome Street, Management, Telescope, Construction, Snowflake, Northwestern Mutual, Figma

Zip , the world’s only intake-to-pay platform, today announced the speaker lineup for its inaugural annual user conference, Zip Forward .

Key Points: 
  • Zip , the world’s only intake-to-pay platform, today announced the speaker lineup for its inaugural annual user conference, Zip Forward .
  • The conference — which will take place on November 8, 2023, in the heart of San Francisco’s Financial District at The Conservatory at One Sansome — features distinguished guest speakers with unique backgrounds and deep expertise in their respective fields.
  • Highlights include a keynote from Zip co-founders Rujul Zaparde and Lu Cheng on their founding story and sessions with executives from Discover Financial, Figma, Kearney, Northwestern Mutual, OpenAI, Snowflake, Two Sigma, UC Irvine Health and WestCap.
  • “Zip is the global standard for intake-to-pay, helping businesses procure with the fastest process, least risk and at the lowest cost.

A Framework to Evaluate the Clinical Utility of Multicancer Early Detection (MCED) Technologies: Balancing the Utilization of Intermediate and Long-term Data

Retrieved on: 
Thursday, September 28, 2023
Reverse-path forwarding, Consortium, Policy, Cancer, Food and Drug Administration, Organization, US, State, Mortality, Food, Medical device, Medical imaging

WASHINGTON, Sept. 28, 2023 /PRNewswire/ -- Cancer screening tests are used to help find cancer before a person has any symptoms, when it may be easier to treat. Multicancer Early Detection (MCED) technologies are emerging as a promising screening tool to not only detect cancer early but also detect cancers that do not currently have an established screening test. MCEDs are a new technology, and long-term results from randomized clinical trials, the standard for evaluating test efficacy and positive patient outcomes, are not yet available. While MCEDs hold great potential to decrease the mortality rates of cancers, definitive clinical evidence about their benefits and risks will not be available for several years.

Key Points: 
  • The Multicancer Early Detection (MCED) Consortium releases a clinical utility framework to assist decision-makers in making judgments about the benefits and risks of MCED technologies.
  • Multicancer Early Detection (MCED) technologies are emerging as a promising screening tool to not only detect cancer early but also detect cancers that do not currently have an established screening test.
  • MCEDs are a new technology, and long-term results from randomized clinical trials, the standard for evaluating test efficacy and positive patient outcomes, are not yet available.
  • There is a need to understand the range of study designs and data sources to understand the risks & benefits of MCEDs.

A Framework to Evaluate the Clinical Utility of Multicancer Early Detection (MCED) Technologies: Balancing the Utilization of Intermediate and Long-term Data

Retrieved on: 
Thursday, September 28, 2023
Reverse-path forwarding, Consortium, Policy, Cancer, Food and Drug Administration, Organization, US, State, Mortality, Food, Medical device, Medical imaging

WASHINGTON, Sept. 28, 2023 /PRNewswire/ -- Cancer screening tests are used to help find cancer before a person has any symptoms, when it may be easier to treat. Multicancer Early Detection (MCED) technologies are emerging as a promising screening tool to not only detect cancer early but also detect cancers that do not currently have an established screening test. MCEDs are a new technology, and long-term results from randomized clinical trials, the standard for evaluating test efficacy and positive patient outcomes, are not yet available. While MCEDs hold great potential to decrease the mortality rates of cancers, definitive clinical evidence about their benefits and risks will not be available for several years.

Key Points: 
  • The Multicancer Early Detection (MCED) Consortium releases a clinical utility framework to assist decision-makers in making judgments about the benefits and risks of MCED technologies.
  • Multicancer Early Detection (MCED) technologies are emerging as a promising screening tool to not only detect cancer early but also detect cancers that do not currently have an established screening test.
  • MCEDs are a new technology, and long-term results from randomized clinical trials, the standard for evaluating test efficacy and positive patient outcomes, are not yet available.
  • While MCEDs hold great potential to decrease the mortality rates of cancers, definitive clinical evidence about their benefits and risks will not be available for several years.

OKX 'Accelerates Web3' at Token2049 with Daniel Ricciardo and Scotty James and On-Track with McLaren Racing at Singapore Grand Prix

Retrieved on: 
Thursday, September 14, 2023
Crypto, Kucoin, CHIJMES, Reverse-path forwarding, Partnership, NFT, Stealth mode, Scuderia AlphaTauri, Polygon, Japanese Grand Prix, Ripple, McLaren F1, Clifford Pier, Singapore Grand Prix, F1, OKX, Growth, Ecosystem, McLaren, Video game, Cryptocurrency, Web3, Bitget, Lantern

Two prominent OKX Ambassadors, Daniel Ricciardo, Scuderia AlphaTauri Formula One driver, and Scotty James, Olympic snowboarder also joined Haider in a fireside chat on how Web3 is changing sports and entertainment.

Key Points: 
  • Two prominent OKX Ambassadors, Daniel Ricciardo, Scuderia AlphaTauri Formula One driver, and Scotty James, Olympic snowboarder also joined Haider in a fireside chat on how Web3 is changing sports and entertainment.
  • In addition, OKX hosted 'OKX Race Club, ' a McLaren-themed fanzone for the Singapore Grand Prix from September 14-17 at CHIJMES , where fans were joined by McLaren F1 Driver Lando Norris and McLaren Racing CEO Zak Brown on September 14 and 15, respectively.
  • OKX Chief Marketing Officer Haider Rafique said: "OKX recognizes the immense potential of Asia Pacific's role in the Web3 landscape.
  • OKX will continue to be on the leading edge of innovation as we rewrite a new system that benefits everyone."

OKX 'Accelerates Web3' at Token2049 with Daniel Ricciardo and Scotty James and On-Track with McLaren Racing at Singapore Grand Prix

Retrieved on: 
Thursday, September 14, 2023
Crypto, Kucoin, CHIJMES, Reverse-path forwarding, Partnership, NFT, Stealth mode, Scuderia AlphaTauri, Polygon, Japanese Grand Prix, Ripple, McLaren F1, Clifford Pier, Singapore Grand Prix, F1, OKX, Growth, Ecosystem, McLaren, Video game, Cryptocurrency, Web3, Bitget, Lantern

Two prominent OKX Ambassadors, Daniel Ricciardo, Scuderia AlphaTauri Formula One driver, and Scotty James, Olympic snowboarder also joined Haider in a fireside chat on how Web3 is changing sports and entertainment.

Key Points: 
  • Two prominent OKX Ambassadors, Daniel Ricciardo, Scuderia AlphaTauri Formula One driver, and Scotty James, Olympic snowboarder also joined Haider in a fireside chat on how Web3 is changing sports and entertainment.
  • In addition, OKX hosted 'OKX Race Club, ' a McLaren-themed fanzone for the Singapore Grand Prix from September 14-17 at CHIJMES , where fans were joined by McLaren F1 Driver Lando Norris and McLaren Racing CEO Zak Brown on September 14 and 15, respectively.
  • OKX Chief Marketing Officer Haider Rafique said: "OKX recognizes the immense potential of Asia Pacific's role in the Web3 landscape.
  • OKX will continue to be on the leading edge of innovation as we rewrite a new system that benefits everyone."

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Retrieved on: 
Thursday, September 14, 2023
Medical Affairs Bureau, Pathway, Committee for Medicinal Products for Human Use, Hypoparathyroidism, PTH, Patient, European, Southern Transcon, European Medicines Agency, Reverse-path forwarding, European Commission, Parathyroid hormone, CHMP, Pharmaceutical industry

COPENHAGEN, Denmark, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended the approval of TransCon PTH (palopegteriparatide) as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. The European Commission’s final decision on the Company’s Marketing Authorisation Application is expected within 67 days after the positive opinion. TransCon PTH is a prodrug of parathyroid hormone (PTH [1-34]) administered once daily.

Key Points: 
  • The European Commission’s final decision on the Company’s Marketing Authorisation Application is expected within 67 days after the positive opinion.
  • TransCon PTH is a prodrug of parathyroid hormone (PTH [1-34]) administered once daily.
  • “We are pleased to have received this positive CHMP opinion for TransCon PTH and look forward to the final European Commission decision,” said Birgitte Volck, M.D., Ph.D., Executive Vice President, Head of Clinical Development & Medical Affairs, Endocrinology Rare Diseases at Ascendis Pharma.
  • Ascendis plans its first European Union launch of TransCon PTH (palopegteriparatide), if approved, in Germany in early 2024.

Nearly 40% of Enterprises Surveyed by expert.ai Are Planning to Build Customized Enterprise Language Models

Retrieved on: 
Thursday, May 11, 2023
Artificial intelligence, ChatGPT, Communication, ESG, Risk, Reverse-path forwarding, LLM, AI, Bias, Freedom, Investment, Privacy, Customer service, Management

BOSTON, May 11, 2023 /PRNewswire/ -- At a time when the hype surrounding Open AI's ChatGPT has prompted 45% of executives to increase their investments in artificial intelligence (AI)*, the new expert.ai research Large Language Models: Opportunity, Risk, and a Path Forward reveals that more than one-third of enterprises (37.1%) are already planning to train and customize language models to meet their business needs.

Key Points: 
  • Successful adoption of enterprise language models will need to overcome significant challenges to effectively, responsibly and securely train them.
  • Almost three-quarters of enterprises surveyed have budget or are discussing adding budget to support large language model (LLM) adoption.
  • "Enterprise specific language models with a human-centered approach are part of the future," says Marco Varone, founder and CTO of expert.ai.
  • Specific enterprise models can be smaller, more efficient, faster and less resource-hungry while still maintaining high performance.

Mental Healthcare Access and Quality Critical but Lacking per National Alliance of Healthcare Purchaser Coalitions and HR Policy Association Employer Survey

Retrieved on: 
Tuesday, April 25, 2023
National Alliance, Reverse-path forwarding, Employment, Policy, Mental health, The National Alliance, Human voice, Mental, Health, Health insurance, Nursing, Marketing

The Voice of the Purchaser Survey on Behavioral Health Support was conducted by the National Alliance of Healthcare Purchaser Coalitions and HR Policy Association and funded by the Path Forward for Mental Health and Substance Use.

Key Points: 
  • The Voice of the Purchaser Survey on Behavioral Health Support was conducted by the National Alliance of Healthcare Purchaser Coalitions and HR Policy Association and funded by the Path Forward for Mental Health and Substance Use.
  • "Our study found a strong employer consensus on what is critical and significant variation in health plan and vendor performance," said Michael Thompson, National Alliance president and CEO.
  • "Many of the services provided, particularly in managing network access, continue to fall short of employer expectations.
  • Findings were presented today at a Path Forward mental health convening of employers, business health coalitions, mental and behavioral health service providers and health plans, and other industry stakeholders.

Progress in New Alzheimer's Therapeutics Based on Biology of Aging Highlighted in Symposium Hosted by Alzheimer's Drug Discovery Foundation (ADDF) at AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Dis

Retrieved on: 
Tuesday, March 21, 2023
Fillit, Reverse-path forwarding, Swedish Exhibition & Congress Centre, LSP, Investment, Drug discovery, Disease, Alzheimer's Drug Discovery Foundation, Ageing, Alzheimer's Research UK, Dementia, Cancer, Cognition, MBA, Research, Brain, Doctor of Philosophy, ARUK, Organization, DSM-IV codes, EQT, International Conference on Emerging Infectious Diseases, Homogeneity and heterogeneity, Wake Forest School of Medicine, Drug development, Gates Ventures, Biology, Entrepreneurship, AD, Building a Future, Therapy, Conference, Pharmaceutical industry, Management, Medical imaging, Alzheimer's disease, MD

NEW YORK, March 21, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation will host a symposium, "Building the Future: Novel Approaches and Innovations in Alzheimer's Research" at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, March 28th through April 1st at the Swedish Exhibition & Congress Centre in Gothenburg, Sweden.

Key Points: 
  • This symposium encompasses two sessions.
  • The second session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," focuses on the biology of aging and promising drugs in the pipeline that target a host of underlying pathologies that contribute to Alzheimer's disease.
  • It features presentations on research, including novel senolytics and repurposing programs, as well as prevention approaches for Alzheimer's and related dementias.
  • These diverse approaches reflect the current Alzheimer's pipeline, where 75% of drugs in clinical trials focus on non-amyloid and tau targets according to a recent report.

Campbell Named to 2023 Bloomberg Gender-Equality Index

Retrieved on: 
Tuesday, January 31, 2023
LGBTQ+, Retail, Consumer, Women, Supermarket, Food, Beverage, Campbell, Woman, Reverse-path forwarding, Mentorship, CPB, I&D, NextUp Comedy, NYSE, Workplace, Parity, Workforce, Campbell Soup Company, Female, Bloomberg, GEI, Nursing, Management, Newsweek

Campbell Soup Company (NYSE:CPB) today was named to the 2023 Bloomberg Gender-Equality Index (GEI), which tracks the performance of public companies committed to transparency in gender-data reporting.

Key Points: 
  • Campbell Soup Company (NYSE:CPB) today was named to the 2023 Bloomberg Gender-Equality Index (GEI), which tracks the performance of public companies committed to transparency in gender-data reporting.
  • The GEI measures gender equality across five pillars: female leadership and talent pipeline, equal pay and gender pay parity, inclusive culture, anti-sexual harassment policies and pro-women brand.
  • Other Campbell programs and benefits in support of gender equality include on-site daycare facilities at Campbell’s headquarters, parental leave policies, adoption assistance, flexible work arrangements and job-sharing opportunities.
  • Campbell has an actionable I&D strategy focused on building capabilities, advocacy and accountability.